Phase II Study of High-Dose Cyclophosphamide in Patients With Refractory Pemphigus

ClinicalTrials.gov ID: NCT00010413

Open the official record

This page only displays public information reproduced from the official ClinicalTrials.gov record NCT00010413. It adds no medical advice, opinions, or eligibility judgments. The official record remains the source of truth for eligibility criteria, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Nov 15, 2026, 7:04 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

OBJECTIVES: I. Determine the response rate and 1-year event-free survival of patients with refractory pemphigus treated with high-dose cyclophosphamide.

Study identification

NCT ID: NCT00010413
Recruitment status: Completed
Study type: Interventional
Phase: Phase 2
Lead sponsor: Johns Hopkins University; Other
Enrollment: 35 participants

Conditions and interventions

Conditions

Pemphigus

Interventions

cyclophosphamide Drug
filgrastim Drug

Drug

Eligibility (public fields only)

Age range: 18 Years to 70 Years
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Apr 1999 (Type not available)
Primary completion: Aug 2007 (Actual)
Completion: Not listed
Last update posted: Oct 2, 2008

Started 1999

United States locations

U.S. sites: 1
U.S. states: 1
U.S. cities: 1

Facility	City	State	ZIP	Site status
Johns Hopkins University School of Medicine	Baltimore	Maryland	21205	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT00010413, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Oct 2, 2008 · Synced Nov 15, 2026